Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date: June 28, 2006
Jurisdiction: Nevada
Headquarters: San Diego, California
This filing serves as a Regulation FD disclosure to distribute investor presentation materials to the public, ensuring equal access to information previously or subsequently shared with analysts and stockholders.
Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a conduit for an attached investor presentation (Exhibit 99.1) rather than a standalone financial report.
Material Changes
No material changes to financial position or operations are detailed within the text of this 8-K. The primary action is the public release of presentation slides.
Guidance, Outlook, and Risks
- Disclosure Content: The filing incorporates by reference "certain slides" used in an investor presentation dated June 28, 2006.
- Forward-Looking Statements: The filing explicitly directs readers to page 2 of Exhibit 99.1 for a discussion of forward-looking statements and associated risks and uncertainties.
- Legal Status: The information is furnished under Item 7.01 and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into future registration statements unless specifically identified.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Investor Presentation dated June 28, 2006) for actual financial data, strategic outlook, and specific risk factors.
- Verify the content of page 2 of Exhibit 99.1 for the full disclosure of forward-looking statement risks.
- Note that this 8-K filing itself contains no numerical financial data.